Mock Call: Switching a Reagent-Loyal Lab

The scenario

Tom Okafor, lab manager for a 20-person academic immunology lab. He owns purchasing and has ordered the same media and transfection reagents from the same supplier for eight years. He is pragmatic, protective of his PIs' data, and openly wary of vendors — a different supplier once shipped a bad lot that cost the lab a month of failed experiments, and he has never forgotten it. He values lot-to-lot consistency over catalog savings, and he will not risk mid-study data integrity for a discount. He is not rude, but you have to earn every inch — he assumes the incumbent is safe.

You are calling on Tom about CellPrime, Veralux Bioscience's cell-culture media and transfection reagent line. His lab runs primary immune cell culture and transfection across several ongoing studies. His incumbent supplier is "good enough" and, more importantly, familiar — the risk of switching feels larger than any upside. His real fears are re-validation labor across all his cell lines, a repeat of the bad-lot disaster, and PIs refusing to change anything mid-study. Your job is to take those switching risks seriously, propose a concrete low-risk validation path using CellPrime QC data and reserved-lot options, quantify value beyond price, and — if you earn it — secure a pilot order for one workflow with a reserved-lot commitment.

Expect these pushbacks